- The FDA has accepted to review Strongbridge Biopharma plc's SBBP marketing application for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome.
- Earlier than anticipated, the Company received the official Day 74 letter from the FDA. Within the Day 74 letter, the FDA set a Prescription Drug User Fee Act (PDUFA) target action date of January 1, 2022, reflecting a projected 10-month standard review period.
- The letter does not mention a plan to hold an advisory committee meeting.
- Endogenous Cushing's syndrome is a rare endocrine disease caused by chronic elevated cortisol exposure, often resulting from a benign tumor of the pituitary gland.
- Price Action: SBBP shares are up 0.9% at $2.29 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
